A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea


About this study

Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age range: 18-60 years old (inclusive).
  • BMI ≤ 40 kg/m^2.
  • Not a current smoker or tobacco user.
  • Gender: Both males and females will be allowed to participate in the study.
  • Target disease or condition: Healthy and OSA subjects.
  • Absence of any chronic medical conditions other than seasonal or environmental allergies, depression, acid reflux and acne.
  • Individuals with untreated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study.
  • On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Ceterizine, Fexofenadine, Desloratadine, Loratadine, etc., depression, acid reflux (such as antacids or PPIs), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
  • Not pregnant or breast feeding and not intending to become pregnant or breast feed.
  • Ability to provide written informed consent.
  • If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.

Exclusion Criteria:

  • Vulnerable study population will be excluded.
  • Presence of chronic kidney disease (creatinine > 2.5 mg/dL) and/or active cancer.
  • Pregnancy.
  • Anemic (hemoglobin < 12.0 g/dL for men and < 11.0 g/dL for women).
  • Smoking.
  • Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors).
  • Blood or plasma donation during the past 2 months.




Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Virend Somers, M.D., Ph.D.

Open for enrollment

Contact information:

CPL OSA Sleep Study


More information


Publications are currently not available

Mayo Clinic Footer